I don't see why the Asian licensing partner wouldn't happen? Prolanta has serious potential given the science and research supporting it. Why wouldn't another company want a piece of a potential breakthrough cancer treatment?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.